跳至主要内容
临床试验/TCTR20220209007
TCTR20220209007已完成1 期

Efficacy and Safety of Kleeb Bua Daeng Formula in Mild Cognitive Impairment Patients

Chao Phya Abhaibhubejhr Hospital Foundation0 个研究点目标入组 40 人开始时间: 2022年2月9日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
40 Years 至 70 Years(—)
性别
All

入选标准

  • MCI patients in Chao Phya Abhaibhubejhr hospital, Prachinburi of Thailand, were enrolled. The inclusion criteria were as follows: Provision of signed informed consent before any study-specific procedure, MoCA (Montreal Cognitive Assesssment)-T score between 19-24, and 40-70 years of age.

排除标准

  • The exclusion criteria were as follows: GFR by Cockcroft formulation less than 40 ml/min, serum alanine aminotransferase and aspartate aminotransferase higher than 2.5 of standard level, patients who receive warfarin, pregnancy or breastfeeding, need for or an anticipated need for oral with any of the following: (a) Cholinesterase inhibitors (b) N-methyl D-aspartate antagonist (NMDA) (c) Cholinesterase inhibitors plus NMDA, and participation in another clinical study with an investigational product at any time during the 30 days before randomization.

研究者

相似试验